Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd has positioned itself strongly within the pharmaco-epigenetics space through collaborations and strategic partnerships, which are likely to enhance revenue growth and increase the adoption of its biomarker technology. The validation of the Nu.Q Lung Cancer Test represents a pivotal opportunity, potentially de-risking the technology and making it more appealing for strategic partnerships with major diagnostic and pharmaceutical players. Additionally, the successful rollout of its automated systems in Japan has already seen adoption by over 1,000 veterinary hospitals, reflecting robust market interest and the potential to significantly boost VolitionRX's revenue from its diagnostic offerings.

Bears say

VolitionRX Ltd faces a negative outlook due to the ongoing challenges in its development of effective diagnostic tests, particularly highlighted by the issues surrounding high false-positive rates in its current study related to pulmonary nodules. These challenges jeopardize the company's ability to deliver reliable and cost-effective solutions, potentially impacting market acceptance and revenue generation. Additionally, the reliance on its Nucleosomics platform amidst significant competition in the diagnostics space raises concerns about the company's long-term financial viability and growth prospects.

Volitionrx Limited (VNRX) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.